Pharmaceutical Co-crystals and Chemistry Characterisation Optimisation of Drug Properties

Live Webinar November 28th, 2018

Co-crystallisation is gaining significant interest as an enabling solution for active pharmaceuticals which have poor or limiting bioavailability and as a mechanism for Intellectual Property (IP) protection.

In the 8th webinar in our series, Concept and our partners Malvern Panalytical, bring together two leading industry experts to present recent developments in the chemistry, regulation and characterization of API co-crystals.

Kim James, Lead Chemist at Concept Life Sciences, will discuss co-crystal fundamental concepts including their design, chemistry, synthesis and scale up. He will present the advantages conferred to the discovery and development pathway through co-crystals exhibiting enhanced drug-like properties, together with the recent evolution in the FDA approach to these forms, and their viability as development candidates.

The presentation from Stjepan Prugovecki (Regional XRD Product Manager EMEA) at Malvern Panalytical will then cover the relevance of crystal structure in the characterization of co-crystals and the methods for determination and refinement of their crystal structure. It will include discussions on structural differences and similarities between co-crystals, salts, polymorphs, hydrates and solvates as well as the role of crystal structure in Intellectual Property Protection and patents. It will finish with analytical methods for identification and stability assessment of co-crystals in a bulk pharmaceutical product.

This webinar will be hosted by Simon Bristow, Chief Technical Officer at Concept Life Sciences. Simon has over 25 years’ experience in pharmaceutical development and API process technology research.

The webinar will be of interest to medicinal chemists, process research specialists, pre-formulation and materials characterization scientists and those involved in pre-clinical drug development.